How Novartis AG Makes Money

The pricing power inherent in the innovative pharma model allows Novartis to charge premium prices in the US market, which accounts for approximately 45% of total global sales. However, this pricing power is increasingly constrained by the US Inflation Reduction Act, which allows Medicare to negotiate drug prices. The company's response has been to shift its focus toward rare diseases and oncology, therapeutic areas where patient populations are smaller, clinical outcomes are more dramatic, and pricing pressure is less severe. The US market remains the most profitable region, contributing approximately 45% of total revenue but an even higher percentage of operating profit due to the significantly higher pricing power for innovative medicines in the United States compared to Europe and Asia. Concurrently, the company is navigating intense regulatory pricing pressure in the US, the world's most profitable pharmaceutical market. Additionally, the company's deep integration with academic medical centers through its clinical trial network creates a feedback loop of real-world data that accelerates regulatory approvals and label expansions. The Chinook assets target IgA nephropathy and atypical hemolytic uremic syndrome, rare conditions where Novartis now holds the only approved or late-stage therapies, granting it temporary monopolies with exceptional pricing power. The company's extensive experience in navigating the complex regulatory landscape for radiopharmaceuticals, which involves coordination between multiple government agencies including the FDA, the Nuclear Regulatory Commission (NRC), and the Department of Transportation (DOT), provides it with a deep institutional knowledge base that accelerates the development and commercialization of new radioligand assets. The company must also navigate the complex and evolving pricing and reimbursement landscape, particularly in the US where the implementation of the Inflation Reduction Act is expected to put significant downward pressure on drug prices.

The decision to abandon low-margin, high-volume generic manufacturing in favor of high-risk, high-reward specialty therapeutics was orchestrated by CEO Vas Narasimhan, who took the helm in 2018 and immediately recognized that the conglomerate structure was destroying shareholder value by masking the true growth rate of the innovative pipeline. The FY2025 financial results reveal a company in the midst of a high-wire act: replacing declining legacy blockbusters with next-generation modalities while maintaining double-digit earnings growth. This pivot has alienated income-focused investors who relied on the steady dividends of the generics business, but it has attracted a new class of growth-oriented institutional capital that values the binary upside of a successful Phase III oncology trial over the single-digit margins of commodity pill manufacturing. The execution of this strategy requires flawless commercial execution, a capability that was severely tested in FY2025 when Entresto, the company's premier cardiovascular franchise, faced generic competition in the United States. This logistical constraint creates a massive barrier to entry for competitors, as it requires the establishment of a decentralized network of nuclear pharmacies and certified treatment centers, a capital-intensive infrastructure that Novartis has spent the last seven years building through strategic acquisitions and organic investment. The ultimate goal of the business model is to achieve a sustainable compound annual growth rate (CAGR) of 5-6% at constant currency through 2030, a target that requires the successful launch of at least eight new molecular entities currently in the late-stage pipeline. The market has rewarded this strategy with a higher valuation multiple, recognizing that a pure-play innovator with a strong pipeline is worth more than a diversified healthcare conglomerate, and the FY2025 financial results provide the empirical evidence that this strategic gamble is currently paying off, even as the company navigates the treacherous waters of the Entresto patent cliff. To mitigate these patent cliff risks, the business model incorporates aggressive inorganic growth. This bolt-on acquisition strategy is designed to fill the revenue gaps left by patent expirations without relying solely on internal discovery. Novartis has invested hundreds of millions of dollars to build a network of specialized nuclear pharmacies and certified treatment centers capable of handling radioactive materials, creating a massive barrier to entry for competitors who would need to replicate this infrastructure from scratch. For Cosentyx, the company has continuously expanded the label to include new indications such as non-radiographic axial spondyloarthritis and enthesitis-related arthritis, while also launching higher-concentration, single-use autoinjectors to improve patient compliance and convenience. The company has consistently returned over 50% of its free cash flow to shareholders through a progressive dividend policy and an aggressive share buyback program, a strategy that has supported the stock price during the transition period between legacy patent cliffs and new product launches. The company's future depends on its ability to execute a 5-6% constant currency sales CAGR through 2030, a target that requires the successful launch of eight late-stage pipeline assets and the continued expansion of its dominant position in radioligand therapy. Novartis's competitive strategy in this space relies on continuous lifecycle management, launching new indications and delivery methods to extend patent life. The most significant competitive threat, however, comes from the rise of specialized biotechnology companies that focus exclusively on single therapeutic areas. To counter this, Novartis has adopted a 'buy and scale' strategy, using its massive balance sheet to acquire clinical-stage biotechs like MorphoSys and Chinook, effectively outsourcing the early-stage discovery risk to the private markets and then using its global commercial infrastructure to maximize the value of the assets. This convenience factor has driven rapid uptake of Kesimpta, allowing Novartis to capture a significant portion of the market despite entering several years after Ocrevus. Novartis has responded by aggressively expanding its oncology pipeline through both internal discovery and external acquisitions, focusing on novel targets and mechanisms of action that have the potential to overcome resistance to existing therapies. The company's acquisition of MorphoSys, for example, was driven by the desire to acquire pelabresib, a BET inhibitor that has shown promise in the treatment of myelofibrosis, a rare blood cancer with limited treatment options. This strategy of identifying unmet medical needs in rare and complex diseases and developing targeted therapies to address them is a core component of Novartis's competitive strategy, allowing the company to avoid the hyper-competitive, price-sensitive markets for common diseases like diabetes and hypertension, and instead focus on areas where it can command premium pricing and achieve high margins. Selling, general, and administrative expenses were tightly controlled, growing at a slower rate than revenue, which contributed to the margin expansion. This capital return strategy is designed to support the stock price during the transition period between legacy patent cliffs and new product launches, signaling management's confidence in the long-term cash generation capabilities of the pure-play innovative model. This substantial R&D investment is critical for maintaining the company's competitive position and driving future growth, and it is allocated across a diverse portfolio of early-stage discovery programs, Phase I and II clinical trials, and large-scale Phase III registrational studies. Selling, general, and administrative (SG&A) expenses were $14.1 billion, or 25.9% of net sales, reflecting the significant commercial investment required to launch and support the company's growing portfolio of innovative medicines. Additionally, the company faces significant headwinds in the Chinese market, which has historically been a key driver of volume growth for its portfolio. The Chinese government's Volume-Based Procurement (VBP) program has forced steep price cuts on older, off-patent drugs, and the National Reimbursement Drug List (NRDL) negotiations have increasingly targeted newer, innovative therapies, compressing margins and limiting the revenue potential of new launches in the region. Novartis has responded by restructuring its commercial organization in China, shifting its focus toward a smaller portfolio of high-value innovative medicines and divesting its low-margin off-patent portfolio to local partners, but the long-term impact of these regulatory pricing pressures on the company's growth trajectory in Asia remains a significant area of uncertainty for investors. Novartis is currently conducting the PSMAddition trial to evaluate Pluvicto in an earlier line of therapy, which, if successful, would expand the addressable patient population by several fold and further entrench the drug's dominance in the prostate cancer treatment algorithm. Novartis AG's growth strategy is built on three specific, named initiatives with clear financial targets: the acceleration of radioligand therapy launches, the aggressive expansion of the rare disease portfolio through bolt-on acquisitions, and the lifecycle management of key immunology franchises. The company has committed to launching at least eight new molecular entities or major label expansions between 2025 and 2030, a pipeline that includes potential blockbusters in oncology, immunology, and cardiovascular disease. The radioligand initiative is the cornerstone of this strategy, with the company investing heavily in manufacturing capacity and clinical trials to expand Pluvicto into earlier lines of prostate cancer and launch new FAP-targeting therapies for solid tumors. The rare disease growth strategy focuses on using the Chinook Therapeutics acquisition to establish Novartis as the leader in complement-mediated diseases. The immunology lifecycle management strategy aims to extend the commercial life of Cosentyx and Kesimpta by launching new indications, combination therapies, and subcutaneous delivery methods. By continuously expanding the clinical utility of these assets, Novartis can defend against biosimilar competition and maintain premium pricing in key markets. To fund these initiatives, the company maintains a disciplined capital allocation framework that prioritizes R&D investment and strategic acquisitions over large-scale, transformational mergers. The execution of this growth strategy requires a highly skilled and motivated workforce, and Novartis has invested heavily in talent acquisition and development to ensure that it has the necessary scientific and commercial expertise to succeed. Novartis has also implemented a comprehensive training and development program for its employees, focusing on building the skills and capabilities required to succeed in the rapidly evolving pharmaceutical industry. The company's culture of innovation and collaboration is a key enabler of its growth strategy, fostering an environment where employees are encouraged to think creatively, take calculated risks, and work together to solve complex scientific and commercial challenges. The growth strategy also includes a strong focus on sustainability and corporate social responsibility, recognizing that the long-term success of the company is inextricably linked to the health and well-being of the communities in which it operates. Novartis has committed to achieving net zero greenhouse gas emissions across its value chain by 2040, and has implemented a comprehensive environmental, social, and governance (ESG) program that focuses on reducing its environmental footprint, promoting diversity and inclusion, and ensuring access to healthcare for underserved populations. The company's ESG initiatives are integrated into its overall business strategy, and its performance against these goals is regularly monitored and reported to stakeholders. The successful execution of Novartis's growth strategy will require the company to navigate a complex and dynamic external environment, characterized by rapid technological change, intense competition, and evolving regulatory and pricing pressures. However, the company's strong scientific heritage, strong pipeline, and disciplined capital allocation strategy provide a solid foundation for future growth, and its commitment to innovation and patient-centricity positions it well to deliver on its strategic objectives and create significant value for all stakeholders. The company projects a 5-6% constant currency sales CAGR from 2025 to 2030, a growth rate that relies heavily on the successful commercial launch of at least eight late-stage pipeline assets currently in Phase III trials. In the rare disease space, the integration of the Chinook Therapeutics assets is expected to drive significant revenue growth in IgA nephropathy and atypical hemolytic uremic syndrome, therapeutic areas where Novartis now holds a near-monopoly position. Novartis has partnered with leading AI companies to identify novel biological targets and predict patient responses to therapy, a strategy that could significantly reduce the time and cost required to bring new drugs to market. In addition to radioligands, Novartis is heavily invested in the development of gene therapies and RNA-based therapeutics, modalities that have the potential to provide curative treatments for rare genetic diseases. The company's pipeline includes several gene therapy programs for inherited retinal diseases, spinal muscular atrophy, and cardiovascular diseases, as well as a strong portfolio of siRNA and mRNA therapeutics developed through its internal research and external partnerships. Novartis has invested heavily in its gene therapy manufacturing facilities in New Jersey and Germany, and has established a dedicated commercial team to support the launch of these complex therapies. The company is also exploring the use of digital biomarkers and wearable devices to collect real-time patient data during clinical trials, which could provide more sensitive and objective measures of drug efficacy and accelerate the regulatory approval process. The successful implementation of these digital health initiatives has the potential to significantly improve the productivity of the company's R&D organization and reduce the attrition rate of clinical candidates, ultimately leading to the faster and more efficient development of new medicines. The company faces intense competition in all of its key therapeutic areas, and the failure of any of its late-stage pipeline assets could have a material adverse impact on its financial performance and growth trajectory. Despite these challenges, Novartis's strong portfolio of innovative medicines, strong pipeline, and disciplined capital allocation strategy position it well to deliver sustained long-term growth and create significant value for its shareholders. However, the conglomerate structure eventually became a burden, masking the true growth rate of the innovative pipeline and depressing the company's valuation multiples.